1 May 2024 in JCO Precision Oncology
PURPOSE: With liquid biopsy's widespread adoption in oncology, an increased number of clonal hematopoiesis–associated mutations (CHm) have been identified in patients with solid tumors. However, its impact on patient outcomes remains unclear. This study aimed to analyze and describe CHm in a cohort of phase I patients. METHODS: Retrospective data collection from medical records and molecular profiles (Foundation One Liquid CDx Assay) was performed before first study drug administration at the Drug Development Department of Gustave Roussy (France) within the STING trial (ClinicalTrials.gov identifier: NCT04932525 ). CHm prevalence was assessed using any and ≥1% variant allele frequency (VAF) in epigenetic modifier genes ( DNMT3A, TET2, and ASXL1). RESULTS: From January 2021 to December 2022, 255 patients were enrolled in a phase I clinical trial. A total of 55% were male, with a median age of 62 years (24-86). Principal tumor locations were GI (27%) and genitourinary (21%). Overall, 104 patients (41%) had at least one CHm in liquid biopsy, with 55 patients (22%) having a VAF of ≥ 1%. The most frequent mutation was DNMT3A 73% at any VAF (n = 76) and 22% at 1% VAF (n = 23). Median progression-free survival (PFS) and overall survival were 3.8 months (m) for the CHm group versus 3.2 m for nonclonal hematopoiesis (CH; P = .08) and 18.26 m CHm versus 15.8 m non-CH ( P = .9), respectively. PFS increased in the CHm population treated with targeted therapy (hazard ratio, 0.6 [95% CI, 0.42 to 0.84]; P = .004). CONCLUSION: CHm was commonly found in patients with solid tumors treated in phase I trials, with a prevalence of 41% in our cohort. The most frequently mutated gene was DNMT3A. The presence of CHm had no impact on the population of patients treated in the phase I trials.
3 February 2026 in Clinical Cancer Research
Purpose: The use of reversible fibroblast growth factor receptor 2 (FGFR) inhibitors leads to the emergence of “undruggable” FGFR2 kinase domain mutations, hampering sequential treatment strategies. Lirafugratinib and futibatinib are irreversible FGFR inhibitors with the most promising clinical activity against FGFR2-driven tumors. Experimental Design: We characterized resistance to lirafugratinib with circulating tumor DNA, tissue whole-exome sequencing, and bulk RNA sequencing in 30 patients with FGFR2-driven cancers, treated in the phase I/II ReFocus trial (NCT04526106) and enrolled in the UNLOCK program at Gustave Roussy. Results: Among the 30 patients included, 18 (60%) had intrahepatic cholangiocarcinoma and 12 (40%) had other tumor types. Twenty-two patients (73%) were FGFR inhibitor–naïve. Among those experiencing primary resistance to lirafugratinib, we identified potential resistance mechanisms in five of six pretreatment samples. Patients with acquired lirafugratinib resistance manifested an unprecedented emergence of FGFR2 mutations in the M538 and/or L618 residues of the kinase domain, documented in 11 of 16 cases (69%). Compared with futibatinib resistance, FGFR2 molecular brake (N550) and gatekeeper (V565) mutations were rare. Leveraging the spectrum of FGFR2 kinase domain mutations at resistance to lirafugratinib and futibatinib, respectively, we identified the complementarity of the two irreversible inhibitors. On the basis of viability assays in FGFR2::BICC1–dependent Ba/F3 models and in vivo studies on patient-derived xenografts, we propose treatment sequences with the two agents. After lirafugratinib progression, three patients received futibatinib and experienced prolonged disease response. Conclusions: The complementary activity of lirafugratinib and futibatinib against FGFR2 kinase domain mutations supports their sequential use when precise resistance mutations are detected in patients.
1 April 2025 in JCO Precision Oncology
1 June 2023 in Journal of Clinical Oncology
11 February 2026 in SSRN Electronic Journal
CRCristina Reboredo Rendo
+12
Background: The HER2DX genomic assay is a validated tool for personalizing care in early-stage HER2-positive breast cancer. This real-world correlative analysis examines its associations with pathological complete response (pCR) and invasive disease-free survival (IDFS) following trastuzumab- and pertuzumab-based neoadjuvant therapy. Materials and methods: This was a retrospective, observational, single-center study of 156 patients with stage I–III HER2-positive breast cancer treated with a dual HER2 blockade–based neoadjuvant therapy between February 2015 and May 2022 at University Hospital A Coruña (Spain). HER2DX and clinicopathological variables were assessed in pretreatment tumor biopsies. Statistical analyses included Fisher’s exact test, logistic regression, Cox proportional hazards models, and Kaplan–Meier estimates. Results: HER2DX was performed in 111 tumors (71.2%). The overall pCR rate was 51.3%. Hormone receptor–positive disease was significantly associated with lower pCR rates (odds ratio [OR] 0.25, 95% CI 0.11–0.50; p<0.001), whereas HER2 immunohistochemistry 3+ showed a non-significant trend toward higher pCR (OR 2.95, 95% CI 0.96–11.08; p=0.075). Median IDFS was not reached, but hormone receptor–positive tumors showed better outcomes (hazard ratio [HR] 3.67, 95% CI 1.02–13.32; p=0.004 by log-rank). The medium–high HER2DX pCR group had higher pCR rates than the low group (odds ratio [OR] 4.83, 95% CI 1.72–14.65; p=0.004). The continuous HER2DX risk score was independently associated with IDFS (hazard ratio [HR] 2.84, 95% CI 1.24–6.48; p=0.010). Conclusions: In this real-world cohort, HER2DX provided independent prognostic and correlative information on pCR and IDFS beyond standard clinicopathological features.